Aldeyra Therapeutics’ stock jumps 11% premarket after announcing positive trial of treatment for allergic conjunctivitis

Aldeyra Therapeutics Inc.’s stock ALDX jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of a treatment for allergic conjunctivitis. The Lexington, Mass.-based company said the Phase 3 trial dubbed Invigorate-2 achieved statistical significance for its primary endpoint and all secondary endpoints. “Consistent with the results of the Phase 3 INVIGORATE Trial and in conjunction with a number of successful Phase 2 and Phase 3 clinical trials in dry eye disease, achievement of the primary endpoint and all secondary endpoints in INVIGORATE-2 supports the potential of reproxalap…